Trial Profile
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: an Open-Label, Single-Arm, Exploratory Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- 16 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Apr 2024.
- 16 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2023.
- 17 Nov 2021 Planned End Date changed from 1 Dec 2025 to 1 Dec 2023.